|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5676978A
(en)
|
1989-02-14 |
1997-10-14 |
Amira, Inc. |
Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
|
|
US5324731A
(en)
|
1989-02-14 |
1994-06-28 |
Amira, Inc. |
Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
|
|
US6040138A
(en)
|
1995-09-15 |
2000-03-21 |
Affymetrix, Inc. |
Expression monitoring by hybridization to high density oligonucleotide arrays
|
|
US5215882A
(en)
|
1989-11-30 |
1993-06-01 |
Ortho Diagnostic Systems, Inc. |
Method of immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization assays
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US5837832A
(en)
|
1993-06-25 |
1998-11-17 |
Affymetrix, Inc. |
Arrays of nucleic acid probes on biological chips
|
|
US5807522A
(en)
|
1994-06-17 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for fabricating microarrays of biological samples
|
|
DE69621507T2
(de)
|
1995-03-28 |
2003-01-09 |
Japan Science And Technology Corp., Kawaguchi |
Verfahren zur molekularen Indexierung von Genen unter Verwendung von Restriktionsenzymen
|
|
US5843974A
(en)
*
|
1995-06-06 |
1998-12-01 |
Eli Lilly And Company |
Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
|
|
US5958342A
(en)
|
1996-05-17 |
1999-09-28 |
Incyte Pharmaceuticals, Inc. |
Jet droplet device
|
|
US6060240A
(en)
|
1996-12-13 |
2000-05-09 |
Arcaris, Inc. |
Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
|
|
US6090556A
(en)
|
1997-04-07 |
2000-07-18 |
Japan Science & Technology Corporation |
Method for quantitatively determining the expression of a gene
|
|
US5994076A
(en)
|
1997-05-21 |
1999-11-30 |
Clontech Laboratories, Inc. |
Methods of assaying differential expression
|
|
ES2276481T3
(es)
|
1997-12-12 |
2007-06-16 |
The University Of Western Ontario |
Peptido apoep1.b novedoso, composiciones y sus usos.
|
|
US6004755A
(en)
|
1998-04-07 |
1999-12-21 |
Incyte Pharmaceuticals, Inc. |
Quantitative microarray hybridizaton assays
|
|
US6048695A
(en)
|
1998-05-04 |
2000-04-11 |
Baylor College Of Medicine |
Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
|
|
US6087112A
(en)
|
1998-12-30 |
2000-07-11 |
Oligos Etc. Inc. |
Arrays with modified oligonucleotide and polynucleotide compositions
|
|
US6316503B1
(en)
|
1999-03-15 |
2001-11-13 |
Tularik Inc. |
LXR modulators
|
|
US8257750B2
(en)
|
1999-04-30 |
2012-09-04 |
Kibow Biotech, Inc. |
Calcium carbonate compositions for preventing or treating hyperphosphatemia
|
|
AU2001280576A1
(en)
|
2000-07-18 |
2002-01-30 |
Uab Research Foundation |
Tissue-specific self-inactivating gene therapy vector
|
|
US20030027335A1
(en)
|
2000-09-07 |
2003-02-06 |
Ruley H. Earl |
Genome engineering by cell-permeable DNA site-specific recombinases
|
|
US20040072868A1
(en)
|
2000-09-18 |
2004-04-15 |
Collins Jon Loren |
Substitued aminopropoxyaryl derivatives useful as agonists for lxr
|
|
AU2002219718A1
(en)
|
2000-12-13 |
2002-06-24 |
Sca Hygiene Products Zeist B.V. |
Process for oxidising primary alcohols
|
|
JP2003033179A
(ja)
|
2001-07-05 |
2003-02-04 |
Asahi Kasei Corp |
可逆的遺伝子導入ベクター
|
|
WO2003082802A1
(en)
*
|
2002-03-27 |
2003-10-09 |
Smithkline Beecham Corporation |
Acid and ester compounds and methods of using the same
|
|
WO2003082205A2
(en)
|
2002-03-27 |
2003-10-09 |
Smithkline Beecham Corporation |
Compounds and methods
|
|
AU2003220558A1
(en)
|
2002-03-27 |
2004-06-03 |
Smithkline Beecham Corporation |
Amide compounds and methods of using the same
|
|
WO2004009765A2
(en)
|
2002-07-19 |
2004-01-29 |
Althea Technologies, Inc. |
Strategies for gene expression analysis
|
|
US20040216178A1
(en)
|
2003-03-03 |
2004-10-28 |
Jones Stephen N |
Regulation of mdm2 function
|
|
US7135575B2
(en)
*
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
|
WO2005007877A2
(en)
|
2003-07-18 |
2005-01-27 |
University Of Massachusetts |
Regulatable promoters for synthesis of small hairpin rna
|
|
ES2342397T3
(es)
|
2003-10-20 |
2010-07-06 |
Nsgene A/S |
Vector virico para su uso en terapia genica in vivo de la enfermedad de parkinson.
|
|
PE20050676A1
(es)
|
2003-12-12 |
2005-11-02 |
Wyeth Corp |
Quinolinas referidas a enfermedades cardiovasculares
|
|
FR2865736B1
(fr)
|
2004-02-02 |
2006-07-14 |
Synt Em |
Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese
|
|
WO2005112620A2
(en)
|
2004-05-18 |
2005-12-01 |
Massachusetts Institute Of Technology |
A cre-lox based method for conditional rna interference
|
|
TW200606157A
(en)
*
|
2004-07-02 |
2006-02-16 |
Sankyo Co |
Suppressant of production of tissue factor
|
|
JP2008505905A
(ja)
|
2004-07-07 |
2008-02-28 |
メルク エンド カムパニー インコーポレーテッド |
ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法
|
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
|
ES2315912T3
(es)
|
2004-10-01 |
2009-04-01 |
F. Hoffmann-La Roche Ag |
Derivados de eter sustituido por hexafluorisopropanol.
|
|
CN101087754B
(zh)
|
2004-12-22 |
2012-01-18 |
霍夫曼-拉罗奇有限公司 |
环己烷衍生物
|
|
SE0500055D0
(sv)
|
2005-01-10 |
2005-01-10 |
Astrazeneca Ab |
Therapeutic agents 3
|
|
SE0500056D0
(sv)
|
2005-01-10 |
2005-01-10 |
Astrazeneca Ab |
Therapeutic agents 4
|
|
KR20070094963A
(ko)
|
2005-01-10 |
2007-09-27 |
아스트라제네카 아베 |
간 ｘ 수용체 조절제로서 이소티아졸-3(2ｈ)-온1,1-디옥사이드 유도체
|
|
WO2006073364A1
(en)
|
2005-01-10 |
2006-07-13 |
Astrazeneca Ab |
Derivatives of isothiazol-3 (2h)-thione 1,1-dioxides as liver x receptor modulators
|
|
SE0500058D0
(sv)
|
2005-01-10 |
2005-01-10 |
Astrazeneca Ab |
Therapeutic agents 5
|
|
KR20070116060A
(ko)
|
2005-03-01 |
2007-12-06 |
와이어쓰 |
신놀린 화합물 및 간 ｘ 수용체 조절제로서의 이의 용도
|
|
CN101146762A
(zh)
|
2005-03-21 |
2008-03-19 |
默克公司 |
取代的芳基和杂芳基衍生物
|
|
WO2007002563A1
(en)
|
2005-06-27 |
2007-01-04 |
Exelixis, Inc. |
Imidazole based lxr modulators
|
|
CN103524392B
(zh)
|
2005-10-07 |
2018-06-01 |
埃克塞利希斯股份有限公司 |
作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
|
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
|
US7790745B2
(en)
|
2005-10-21 |
2010-09-07 |
Bristol-Myers Squibb Company |
Tetrahydroisoquinoline LXR Modulators
|
|
WO2007092065A2
(en)
|
2005-11-14 |
2007-08-16 |
Irm Llc |
Compounds and compositions as lxr modulators
|
|
WO2007081335A1
(en)
|
2006-01-12 |
2007-07-19 |
Merck & Co., Inc. |
Therapeutic compounds for treating dyslipidemic conditions
|
|
US20100279918A1
(en)
|
2006-03-20 |
2010-11-04 |
Burnham Institute For Medical Research |
Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents
|
|
WO2008011071A2
(en)
*
|
2006-07-19 |
2008-01-24 |
The Regents Of The University Of California |
Interactions of hedgehog and liver x receptor signaling pathways
|
|
TW200825054A
(en)
|
2006-10-18 |
2008-06-16 |
Wyeth Corp |
Quinoline compounds
|
|
US8324367B2
(en)
|
2006-11-03 |
2012-12-04 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
|
EP2098515B1
(en)
|
2006-11-30 |
2012-02-08 |
Kowa Company, Ltd. |
Substituted carbinol compound
|
|
WO2008073825A1
(en)
|
2006-12-08 |
2008-06-19 |
Exelixis, Inc. |
Lxr and fxr modulators
|
|
JP2008179562A
(ja)
|
2007-01-24 |
2008-08-07 |
Kowa Co |
Ｌｘｒアゴニスト
|
|
US8993628B2
(en)
|
2007-02-23 |
2015-03-31 |
City Of Hope |
Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof
|
|
MX2009012474A
(es)
|
2007-05-18 |
2009-12-18 |
Wyeth Corp |
Compuestos de quinazolina.
|
|
WO2009005793A2
(en)
|
2007-06-29 |
2009-01-08 |
Avi Biopharma, Inc. |
Tissue specific peptide conjugates and methods
|
|
CN103772299A
(zh)
|
2007-08-13 |
2014-05-07 |
霍夫曼-拉罗奇有限公司 |
新型哌嗪酰胺衍生物
|
|
TW200922582A
(en)
|
2007-08-20 |
2009-06-01 |
Organon Nv |
N-benzyl, N'-arylcarbonylpiperazine derivatives
|
|
US8039493B2
(en)
|
2007-09-27 |
2011-10-18 |
Hoffmann-La Roche Inc. |
Biaryl sulfonamide derivatives
|
|
ES2463665T3
(es)
*
|
2007-10-04 |
2014-05-28 |
Stella Aps |
Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
|
|
MX2010005104A
(es)
|
2007-11-09 |
2010-08-04 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
|
|
WO2009075836A2
(en)
*
|
2007-12-10 |
2009-06-18 |
The Brigham And Women's Hospital, Inc. |
Rap variants for drug delivery
|
|
BRPI0821315A2
(pt)
|
2007-12-21 |
2019-09-24 |
Wyeth Llc |
compostos benzimidazol
|
|
WO2009086130A1
(en)
|
2007-12-21 |
2009-07-09 |
Wyeth |
Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
|
|
CN101952293A
(zh)
|
2007-12-21 |
2011-01-19 |
惠氏有限责任公司 |
吡唑并[1,5-a]嘧啶化合物
|
|
BRPI0822237A2
(pt)
|
2007-12-21 |
2015-06-30 |
Wyeth Llc |
Compostos de imidazo [1,2-a] piridina
|
|
EP2248811B1
(en)
|
2008-02-29 |
2012-11-14 |
Kowa Company, Ltd. |
2-oxochromene derivative
|
|
WO2009148915A2
(en)
*
|
2008-05-29 |
2009-12-10 |
Bristol-Myers Squibb Company |
Methods for predicting patient response to modulation of the co-stimulatory pathway
|
|
WO2010002982A1
(en)
*
|
2008-07-01 |
2010-01-07 |
Cognosci, Inc. |
Methods of treating cancer with apoe peptides
|
|
PL2342226T3
(pl)
|
2008-09-26 |
2017-01-31 |
Dana-Farber Cancer Institute, Inc. |
Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
|
|
WO2010101888A2
(en)
*
|
2009-03-02 |
2010-09-10 |
Biocure Pharma, Llc |
Methods and compositions for treatment of tumor metastasis
|
|
HRP20170194T1
(hr)
|
2009-05-28 |
2017-05-19 |
Exelixis Patent Company Llc |
Lxr modulatori
|
|
WO2011115892A1
(en)
*
|
2010-03-15 |
2011-09-22 |
Griffin Patrick R |
Modulators of the retinoic acid receptor-related orphan receptors
|
|
WO2011130426A2
(en)
*
|
2010-04-13 |
2011-10-20 |
New York University |
Compositions and methods for treatment of melanoma
|
|
US20130090258A1
(en)
|
2010-06-16 |
2013-04-11 |
National University Corporation Hamamatsu University School Of Medicines |
Method for detecting colorectal tumor
|
|
EP2474617A1
(en)
*
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
|
US20130004481A1
(en)
*
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
|
AR088728A1
(es)
|
2011-03-25 |
2014-07-02 |
Bristol Myers Squibb Co |
Moduladores de lxr como prodroga de imidazol
|
|
US20130071403A1
(en)
*
|
2011-09-20 |
2013-03-21 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
ES2765573T3
(es)
*
|
2012-08-13 |
2020-06-09 |
Univ Rockefeller |
Tratamiento y diagnóstico de melanoma
|